Search
Recent Comments
- Simon Madorsky, MD on Upper Lip Reconstruction – Myocutaneous Island Flap
- Carina on Upper Lip Reconstruction – Myocutaneous Island Flap
- Simon Madorsky, MD on Perineural Invasion
- Simon Madorsky, MD on Nonhealing Calvarium of the Scalp following Mohs Excision
- Joseph Ruffino on Nonhealing Calvarium of the Scalp following Mohs Excision
Tags
5-FU actinic cheilitis Actinic Keratoses Adnexal Carcinoma Aldara Atypical Melanocytic Lesion Basal Cell carcinoma basosquamous cell carcinoma CT/PET scan DNA testing fasciocutaneous island flap FDA genetics hedgehog pathway histopathology imiquimod immunohistochemistry immunosuppressed patient immunosuppressed transplant patients lentigo maligna melafind melanocytic lesion melanoma melanoma-in-situ metastases microcystic adnexal carcinoma Mohs surgery mucosal advancement myocutaneous island flap nose reconstruction osteoradionecrosis perineural invasion photodynamic therapy radiation complications radiation therapy Reflectance confocal microscopy scalp carcinoma treatment SCCa Sentinel Lymph Node Biopsy skin cancer skin cancer radiation Solaraze Squamous cell carcinoma superficial radiotherapy vismodegib
Tag Archives: Xeloda
by Nabil Phillips, MD and Simon Madorsky, MD Capecitabine, an oral chemotherapeutic drug, is a prodrug of 5-FU (fluorouracil) – the most widely used topical chemotherapeutic agent for basal and squamous cell carcinomas. Capecitabine is better known by its brand … Continue reading
Given the predisposition of transplant patients to squamous cell carcinomas of the skin (SCCa), changing the patient’s immunosuppressive regimen to sirolimus (Rapamune) needs consideration. Continue reading